Complete 2026 Guide to Pharmaceutical Supply Chain Visibility
Every year, falsified and substandard medicines cause hundreds of thousands of preventable deaths globally. The World Health Organization estimates that 1 in 10 medical products in low- and middle-income countries is falsified or substandard. For pharmaceutical manufacturers, distributors, and dispensers, the answer to this crisis lies in one phrase: track and trace pharma.
Track and trace in pharma refers to the end-to-end ability to follow a medicinal product from the manufacturing line to the patient’s hand, recording every movement, every transfer of ownership, and every status change along the way. As of 2026, more than 78 countries enforce some form of track-and-trace mandate, and the United States, European Union, India, Russia, China, Brazil, Turkey, and the Gulf states have made it the legal foundation of pharmaceutical commerce.
This guide explains how track and trace pharma systems work, the regulations they satisfy, the technology stack behind them, and how to build a future-proof traceability strategy.
What Is Track and Trace in Pharma?
Track and trace is the practice of capturing, storing, and exchanging supply-chain event data for every unit of pharmaceutical product. It has two complementary parts:
- Track, knowing in real time where a specific pack is right now in the supply chain
- Trace, being able to look backward and reconstruct where it has been, who handled it, and when
To accomplish both, a track-and-trace system depends on three foundational technologies:
- Serialization, every saleable pack carries a unique identifier (typically GS1 GTIN + Serial Number + Batch + Expiry, encoded in a 2D DataMatrix)
- Aggregation, parent-child relationships link units → bundles → cases → pallets
- Event capture and exchange, every commissioning, packing, shipping, receiving, and dispensing event is recorded and shared between trade partners using the EPCIS standard
Without all three layers working together, traceability remains incomplete.
Why Track and Trace Pharma Matters
1. Patient Safety
A verified pack is a safe pack. Track and trace lets pharmacies and hospitals confirm at the point of dispense that a medicine is genuine, unexpired, and not flagged as recalled or stolen.
2. Regulatory Mandate
The US DSCSA reached full enforcement in 2025. The EU FMD has required dispense-point verification since 2019. India, Russia, China, Brazil, Saudi Arabia, the UAE, and Turkey all operate national track-and-trace systems. Non-compliance increasingly means losing market access.
3. Faster, More Surgical Recalls
Instead of pulling an entire batch of millions of units, a granular track-and-trace system lets manufacturers and regulators recall only the affected serial numbers, saving cost, reducing waste, and protecting patient supply.
4. Anti-Diversion and Anti-Counterfeit Defense
When stolen or diverted packs reappear in the legitimate supply chain, track-and-trace event histories expose the anomaly instantly.
5. Supply Chain Intelligence
Track-and-trace data, when properly mined, reveals bottlenecks, demand patterns, cold-chain excursions, and high-risk lanes, turning compliance data into operational advantage.
The Regulatory Landscape: Where Track and Trace Is Mandatory
| Region | Regulation | Model |
| United States | DSCSA (Drug Supply Chain Security Act) | Full electronic traceability via EPCIS partner-to-partner data exchange |
| European Union | FMD (Falsified Medicines Directive) | Point-of-dispense verification against EMVS |
| India | DGFT iVEDA (exports) + CDSCO domestic mandate | Barcoding + central portal reporting |
| Russia | Chestny ZNAK / CRPT | National repository with crypto-enabled DataMatrix |
| Turkey | ITS (İlaç Takip Sistemi) | Government-managed track-and-trace with full aggregation |
| South Korea | KPIS | Centralized national system |
| UAE | Tatmeen | National repository with sequential aggregation reporting |
| Saudi Arabia | SFDA RSD | National repository, full lifecycle reporting |
| Brazil | ANVISA SNCM | National track-and-trace |
| China | NMPA national coding system | Government-issued codes and centralized reporting |
Every one of these regimes requires the same underlying capability: end-to-end serial-level traceability.
How a Track and Trace Pharma System Works, Step by Step
Step 1: Serialization at the Packaging Line
A unique GS1 DataMatrix code is printed on every saleable pack. Vision systems verify print quality, and rejected packs are removed.
Step 2: Aggregation
Units are packed into bundles, cases, and pallets. Each hierarchical relationship is recorded so scanning the outer case reveals every serial number inside.
Step 3: Commissioning Event
The plant’s Level 3 (site) and Level 4 (enterprise) serialization systems generate an EPCIS “commissioning” event marking each pack as live in the legitimate supply chain.
Step 4: Shipping Event
When the manufacturer ships product to a distributor, an EPCIS “shipping” event with full Transaction Information (TI), Transaction History (TH), and Transaction Statement (TS) is transmitted to the trade partner.
Step 5: Receiving and Onward Movement
The distributor confirms receipt with a “receiving” event. As product moves to dispensers, every transfer of ownership is recorded.
Step 6: Verification at Dispense
- Under EU FMD, the pharmacist scans the pack and queries the EMVS to confirm authenticity.
- Under DSCSA, dispensers verify suspect packs through the Verification Router Service (VRS).
Step 7: Decommissioning
Once dispensed to the patient, the pack is marked “decommissioned”, preventing it from being recycled into the supply chain.
Each event answers four critical questions: What, When, Where, and Why.
The Technology Stack Behind Track and Trace Pharma
Hardware Layer
- High-resolution thermal-inkjet or laser coders
- Vision inspection cameras
- Reject and verification mechanisms
- Aggregation stations (manual, semi-automatic, fully automatic)
- Mobile and warehouse scanners
Software Layer
- Line-level controllers (L2), orchestrate hardware
- Site-level serialization (L3), manage serial numbers, aggregation, and quality data
- Enterprise serialization platform (L4), central repository, ERP integration, multi-site management
- Network/regulatory gateway (L5), connects to EMVS, VRS, national hubs, trading partners
Data Standards: The Importance of EPCIS
EPCIS (Electronic Product Code Information Services), maintained by GS1, is the global standard for sharing supply-chain visibility data. It defines:
- The data model, what, when, where, why
- The vocabulary, common business steps (commissioning, packing, shipping, receiving)
- The interfaces, how systems exchange this data
EPCIS 1.2 is the most widely deployed version; EPCIS 2.0 (JSON-based, REST API-native) is becoming the new standard for cloud-first pharma networks.
A common challenge: while EPCIS is a standard, no two implementations are identical. Trade-partner onboarding still requires data-checker tools, mapping rules, and exception management.
Track and Trace vs. Serialization vs. Aggregation, What’s the Difference?
| Concept | What It Does | Example |
| Serialization | Assigns a unique identifier to each pack | Each carton gets its own GTIN+Serial+Batch+Expiry |
| Aggregation | Links parent-child packaging hierarchies | “Case A2391 contains units 0001–0100” |
| Track and Trace | Records and exchanges every movement event | “Pack 0042 shipped from Site X on May 19, received by Distributor Y on May 22” |
You cannot have meaningful track-and-trace without serialization, and you cannot have efficient track-and-trace at scale without aggregation.
Common Pain Points in Pharma Track and Trace (and How to Solve Them)
1. Trading Partner Onboarding
Every connection, manufacturer to wholesaler to dispenser, requires data mapping and testing. Solution: use platforms with pre-built partner networks and automated onboarding workflows.
2. Exception Management
Mismatched serial numbers, missing aggregations, late EPCIS files. Solution: data-checker modules and AI-assisted exception triage.
3. Master Data Inconsistencies
GTINs, NDCs, product names, and dosage details must be synchronized across ERP, MES, and serialization systems before go-live.
4. Multi-Market Complexity
One product may need to comply with DSCSA, EU FMD, India iVEDA, and Russia CRPT simultaneously. Solution: multi-tenant cloud platforms with country-specific compliance modules.
5. Validation Burden
GAMP 5, 21 CFR Part 11, and EU Annex 11 documentation. Solution: vendors that ship pre-validated solution packages.
Track and Trace in India, A Regional Snapshot
India is one of the world’s largest pharmaceutical exporters, supplying generics to more than 200 countries. Its track-and-trace framework has two layers:
- Exports, mandatory barcoding on primary, secondary, and tertiary packs, with serial-number reporting to the DGFT iVEDA portal
- Domestic, the Top 300 brands mandate (under the Drugs and Cosmetics Rules amendment) requires QR codes on primary packaging with product identification and traceability data
For Indian manufacturers and exporters, choosing a track-and-trace solution that handles both Indian and destination-country regulations is critical.
How to Build a Future-Ready Track and Trace Strategy
- Start with master data, clean, governed GTIN and product hierarchy data is the foundation
- Choose a cloud-native, multi-tenant platform, to scale across sites, markets, and partners without re-platforming
- Adopt EPCIS 2.0 early, it is the future of partner exchange
- Build an aggregation discipline even where not legally mandated, most large distributors now expect it commercially
- Invest in trading-partner onboarding tooling, every new partner is a potential failure point
- Treat traceability data as an asset, feed it into recall management, supply-chain analytics, and AI-driven anomaly detection
- Prepare for the next layer of regulation, Digital Product Passports, blockchain-anchored traceability, and crypto-DataMatrix are coming fast
The Future of Track and Trace in Pharma
By 2027–2028, expect:
- AI-powered traceability analytics, anomaly detection, predictive recall, and diversion identification
- Blockchain-anchored event ledgers, already piloted in Ethiopia and India
- Digital Product Passports (EU), extending traceability to include sustainability and ingredient origin data
- Direct-to-patient verification apps, patients scanning packs with smartphones to confirm authenticity
- Crypto-enhanced DataMatrix, spreading from Russia and Kazakhstan into more emerging markets
- Convergence with cold-chain IoT, real-time temperature and location data integrated with traceability events
Track and trace is evolving from a compliance obligation into a real-time intelligence layer for the pharmaceutical supply chain.
Frequently Asked Questions
Q1. Is track and trace the same as serialization? No. Serialization is the act of assigning unique identifiers; track and trace is the system that records and exchanges what happens to those serialized packs across the supply chain.
Q2. What is EPCIS, and why is it critical for track and trace? EPCIS is the GS1 standard for capturing and sharing supply-chain event data. It is the universal language that lets manufacturers, distributors, and dispensers exchange traceability information in a standardized format.
Q3. Do small pharmacies need to comply with track-and-trace requirements? Yes. Under the US DSCSA, small dispensers must meet the full requirements by November 2026. Under the EU FMD, all dispensing pharmacies must verify packs at the point of dispense.
Q4. How long does a track-and-trace implementation take? 8–14 weeks per packaging line is typical, with full enterprise rollouts running 9–18 months for global manufacturers.
Q5. Is aggregation mandatory for track and trace? It is legally required in some jurisdictions (Turkey, parts of the US DSCSA workflow) and commercially required by most major wholesalers, even where regulators leave it voluntary (EU FMD).
Q6. Can track-and-trace data be used for purposes beyond compliance? Absolutely. Leading manufacturers use it for AI-driven recall management, supply-chain analytics, anti-diversion intelligence, and demand sensing.
Track and trace pharma is no longer a future ambition, it is the operating reality of the global pharmaceutical supply chain. With DSCSA fully enforced in the US, FMD mature across the EU, and 78+ other countries mandating traceability, every manufacturer, distributor, and dispenser must operate within a serialized, event-captured, EPCIS-enabled ecosystem.
The companies winning in 2026 and beyond are those treating track and trace not as a checkbox, but as a strategic data asset, securing patients, satisfying regulators, accelerating recalls, and unlocking smarter supply-chain decisions.
